Download PDF
Thromb Haemost 1997; 78(01): 656-660
DOI: 10.1055/s-0038-1657607
Plasminogen activator inhibitor I (PAI-1)
Schattauer GmbH Stuttgart

PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events

I Juhan-Vague
Laboratory of Hematology, University Hospital Timone, Marseille, France
,
M C Alessi
Laboratory of Hematology, University Hospital Timone, Marseille, France
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127-136
    PubMedGoogle Scholar
  • 2 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
    CrossrefPubMedGoogle Scholar
  • 3 Eschwege E, Richard JL, Thibult N, Ducimetière P, Wamet JM, Claude JR, Rosselin GE. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985; 15: 41-46
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsu-linemia. The key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-422
    CrossrefPubMedGoogle Scholar
  • 5 Desprès JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Mooijani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Eng J Med 1996; 334: 952-957
    CrossrefPubMedGoogle Scholar
  • 6 Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in NIDDM. Ann Med 1996; 28: 371-380
    PubMedGoogle Scholar
  • 7 Samad F, Loskutoff DJ. The fat mouse: A powerful genetic model to study the molecular mechanisms of elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thromb Haemostas (this issue).
    Google Scholar
  • 8 Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes. in press
    Google Scholar
  • 9 Bjömtorp P. “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-496
    CrossrefPubMedGoogle Scholar
  • 10 Larsson B, Svärdsud DK, Welin L, Wilhelmsen L, Bjömtorp P, Tibbin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men bom in 1913. Br Med J 1984; 288: 1401-1404
    CrossrefPubMedGoogle Scholar
  • 11 Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-190
    CrossrefPubMedGoogle Scholar
  • 12 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambon JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemostas 1995; 74: 837-841
    PubMedGoogle Scholar
  • 13 Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42
    CrossrefPubMedGoogle Scholar
  • 14 Eriksson P, Kallin B, van’t Hooft, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855
    CrossrefPubMedGoogle Scholar
  • 15 Dawson SJ, Wiman B, Hamsten A, Green F, Hamphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor 1 (PAI-1) gene respond differently to interleukin 1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745
    PubMedGoogle Scholar
  • 16 Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Family study of metabolic and genetic determinants of PAI-1 activity and PAI-1 antigen plasma concentrations. The Stanislas cohort study. Thromb Haemostas XVIth ISTH Congress, Florence. 1997. (abst)
    Google Scholar
  • 17 Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 03-09
    PubMedGoogle Scholar
  • 18 Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-2063
    CrossrefPubMedGoogle Scholar
  • 19 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253
    CrossrefPubMedGoogle Scholar
  • 20 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462
    CrossrefPubMedGoogle Scholar
  • 21 Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: A cross-sectional study in Norsjö, Sweden. J Clin Epidemiol 1989; 42: 719-723
    CrossrefPubMedGoogle Scholar
  • 22 Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non insulin ' dependent) diabetic subjects. Diabetologia 1990; 33: 532-537
    CrossrefPubMedGoogle Scholar
  • 23 Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-1873
    CrossrefPubMedGoogle Scholar
  • 24 Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47: 513-524
    CrossrefPubMedGoogle Scholar
  • 25 Me Gill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-109
    CrossrefPubMedGoogle Scholar
  • 26 Gray RP, Vidya MA, Patterson DLH, Yudkin JS. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemostas 1995; 73: 261-267
    PubMedGoogle Scholar
  • 27 Bavenholm P, Proudler A, Silveira A, Crook D, Blombäck M, de Faire U, Hamsten A. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Thromb Haemostas 1995; 73: 568-575
    PubMedGoogle Scholar
  • 28 Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989; 03: 51-53
    PubMedGoogle Scholar
  • 29 Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non diabetic obese subjects. Thromb Haemostas 1987; 57: 326-328
    PubMedGoogle Scholar
  • 30 Estelles A, Aznar J, Tormo G, Sapena P, Tormo V, Espana F. Influence of a rehabilitation sports program on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 1989; 55: 203-212
    CrossrefPubMedGoogle Scholar
  • 31 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988; 60: 491-494
    PubMedGoogle Scholar
  • 32 Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073
    CrossrefPubMedGoogle Scholar
  • 33 Potter Van Loon BJ, de Bart ACW, Radder JK, Frolich M, Kluft C, Meindors AE. Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor 1 concentration in humans. Fibrinolysis 1990; 4: 93-94
    PubMedGoogle Scholar
  • 34 Raccah D, Alessi MC, Seelies V, Menart C, Juhan-Vague I, Vague P. Plasminogen activator inhibitor activity in various type of endogenous hypertriglyceridemia. Fibrinolysis 1993; 7: 171-176
    PubMedGoogle Scholar
  • 35 Folsom AR, Qamhieh HT, Wing RR, Jeffrey RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162-169
    CrossrefPubMedGoogle Scholar
  • 36 Alessi MC, Parrot G, Guenoun E, Seelies V, Vague P, Juhan-Vague I. Relation between plasma PAI activity and adipsin levels. Thromb Haemostas 1995; 74: 1200-1202
    PubMedGoogle Scholar
  • 37 Sawdey S, Loskutoff DJ. Regulation of murine type 1 plasminogen activity inhibitor (PAI-1) gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor a and transforming growth factor b. J Clin Invest 1991; 8: 1346-1353
    PubMedGoogle Scholar
  • 38 Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor 1 in murine adipose tissue in vivo. J Clin Invest 1996; 97: 37-46
    CrossrefPubMedGoogle Scholar
  • 39 Lundgren CH, Brown SL, Nordt TD, Sobel BE, Fujii S. Elaboration of type 1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-110
    CrossrefPubMedGoogle Scholar
  • 40 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568-582
    CrossrefPubMedGoogle Scholar
  • 41 Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Med 1996; 02: 800-803
    CrossrefPubMedGoogle Scholar
  • 42 Vague P, Juhan-Vague I, Chabert V, Alessi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in non diabetic obese women. Metabolism 1989; 38: 913-915
    CrossrefPubMedGoogle Scholar
  • 43 Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengbom L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 1044-1048
    CrossrefPubMedGoogle Scholar
  • 44 Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vase Biol 1996; 16: 368-374
    CrossrefPubMedGoogle Scholar
  • 45 Henry M, Chomiki N, Scarabin PY, Alessi MC, Pereitti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I. Five frequent polymorphisms of plasminogen activator inhibitor 1 gene: Lack of association between genotypes, PAI activity and triglycerides levels in a healthy population. Arterioscler Thromb Vase Biol. in press
    Google Scholar
  • 46 Mansfield MW, Strickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor 1 in caucasian patients with non insulin dependent diabetes mellitus. Thromb Haemostas 1995; 74: 842-848
    PubMedGoogle Scholar
  • 47 Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079
    CrossrefPubMedGoogle Scholar
  • 48 Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with sever angina pectoris. Eur Heart J 1991; 12: 157-161
    CrossrefPubMedGoogle Scholar
  • 49 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641
    CrossrefPubMedGoogle Scholar
  • 50 Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168
    CrossrefPubMedGoogle Scholar
  • 51 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tarazzi L, Tremoli E, Pozzili E, Turri M. for the PLAT Group Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993; 13: 1412-1417
    CrossrefPubMedGoogle Scholar
  • 52 Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris. Relation to gender, age and acute-phase reaction. Thromb Haemostas 1995; 73: 561-567
    PubMedGoogle Scholar
  • 53 ECAT Angina Pectoris Study Group. ECAT Angina Pectoris Study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 08-17
    PubMed
  • 54 Bosma PJ, van den Berg EA, Kooistra T. Human plasminogen activator inhibitor 1 gene. Promoter and structural gene nucleotide sequences. J Biol Chem 1988; 263: 9129-9141
    PubMedGoogle Scholar
  • 55 Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of t-PA and t-PA/PAI-1 complex: Relationship to elevated t-PA antigen in patients with high PAI-1 activity levels. Circulation. in press
    Google Scholar
  • 56 Charlton PA, Faint RW, Bent F, Bryans J, Mackie I, Machin S, Bevan P. A series of low molecular weight inhibitors of plasminogen activator inhibitor (PAI-1) increase fibrinolysis and protect against thrombus formation in the rat. Thromb Haemostas 1995; 73: 1005 (abst)
    PubMedGoogle Scholar